EGM
ARQT icon

Engineers Gate Manager’s Arcutis Biotherapeutics ARQT Stock Holding History

Engineers Gate Manager’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.55M Sell
65,977
-20,628
-24% -$526K 0.02% 837
2025
Q4 		$2.52M Buy
86,605
+40,322
+87% +$1.03M 0.03% 602
2025
Q3 		$872K Sell
46,283
-51,322
-53% -$809K 0.01% 1225
2025
Q2 		$1.37M Buy
97,605
+31,482
+48% +$441K 0.02% 950
2025
Q1 		$1.03M Buy
+66,123
New +$932K 0.02% 1039
2024
Q4 		– Sell
-34,076
Closed -$317K – 2211
2024
Q3 		$317K Buy
34,076
+7,676
+29% +$75.7K 0.01% 1596
2024
Q2 		$246K Buy
+26,400
New +$239K 0.01% 1563

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return